Summary
BTC (including cholangiocarcinoma and gallbladder cancer) is a challenging malignancy with rising global incidence, especially in Asia and Latin America, driven by risk factors like chronic inflammation and liver flukes; ~65,000 incident cases in 7MM in 2025, projected to grow by 2036, with highest cases in ≥80 age group and TP53 mutations dominant.
Limited curative surgery due to late diagnosis; platinum-based chemo as backbone for advanced disease, now enhanced by first-line immunotherapies like pembrolizumab (KEYTRUDA) + chemo and durvalumab (IMFINZI) + gem/cisplatin; targeted approvals include FGFR inhibitors (pemigatinib, futibatinib), IDH1 inhibit...
